SPA
DAWN

Sherbrooke Park Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History

Sherbrooke Park Advisers’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,457
Closed -$80.8K – 286
2025
Q3 		$80.8K Sell
11,457
-13,541
-54% -$93.2K 0.04% 467
2025
Q2 		$162K Buy
+24,998
New +$172K 0.07% 421
2025
Q1 		– Sell
-14,865
Closed -$188K – 686
2024
Q4 		$188K Buy
+14,865
New +$207K 0.06% 599

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's DAWN Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 11,457 shares — an estimated $80.8K sold.

Sherbrooke Park Advisers first reported a position in DAWN in Q4 2024 and held it in 3 quarters. The position peaked at $188K in Q4 2024. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 11,457 Day One Biopharmaceuticals shares in Q4 2025, an estimated $80.8K.
  • Sherbrooke Park Advisers first reported a position in Day One Biopharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Day One Biopharmaceuticals position peaked at $188K in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.